Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Field Alert Report

Field Alert Report

View Detailed Analysis

Analytics Overview

4
Form 483s Issued
1
483s converted to WL
4
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
15 Dec 2023
Sun Pharmaceutical Industries Limited
Drugs
27 Oct 2023
Dr. Reddy's Laboratories Ltd.
Drugs
15 Sep 2023
Samsung Bioepis Co., Ltd.
Drugs
17 Feb 2023
Cipla Limited
Drugs
08 Jul 2011
Novartis Consumer Health
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Pratik S Upadhyay
2
0
Saleem A Akhtar
2
1
Jose E Melendez
1
1
Scott N Lim
1
0
TITLE/ COMPANY Issue Date Status Details
Field Alert Report was not submitted within three working days of receipt of information concerning significant chemical, physical, or other change or deterioration in a distributed drug product
Sun Pharmaceutical Industries Limited
15 Dec 2023 Normal Justification: The issue specifically relates to the failure to submit necessary Field Alert Reports as mandated by both FDA regulations and internal SOPs, evidencing a direct linkage to the Field Alert Report process type.
Excerpt: "An (b) (4) -Field Alert Report was not submitted within three working days of receipt of information concerning significant chemical, physical, or other change or deterioration in a distributed drug product."
View Details
failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications
Dr. Reddy's Laboratories Ltd.
27 Oct 2023 Normal Justification: The delay in filing the Field Alert Reports and improper closure without proper evaluation highlights a critical gap in the Field Alert Report handling process.
Excerpt: The firm initiated a separate OOS investigation and filed a Field Alert on 25-Jan-2021 to the agency.
View Details
Failure to submit each post marketing 15-day alert and post marketing 15-day alert follow up report as required
Samsung Bioepis Co., Ltd.
15 Sep 2023 Normal Justification: The observation pertains to the delay in submission of post marketing 15-day alert reports, directly tying it to the Field Alert Report process type.
Excerpt: Failure to submit each post marketing 15-day alert and post marketing 15-day alert follow up report as required.
View Details
An Field Alert Report was not submitted within of receipt of information concerning a failure of one or more distributed batches of a drug to meet the specifications established for it in the application.
Cipla Limited
17 Feb 2023 Normal Justification: The observation explicitly mentions the failure to submit the Field Alert Report as per SOP 1035-G-0014, highlighting a direct issue with the Field Alert Report process.
Excerpt: Quality Unit failed to submit a Field Alert Report (FAR) as required under SOP (b) (4) (1035-G-0014, Version: 7.0), "Field Alert Report" for complaints received.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.